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A B S T R A C T  
Objective: To accomplish the comparative analysis of clinical features and laboratory findings in Helicobacter Pylori 
positive and negative patients with Immune thrombocytopenia. 
Patients and Methods: This cross sectional study was conducted from May 2013 to Nov 2014 at Hematology Unit, 
Liaquat National Hospital, Karachi. During the study duration, 59 adult patients, diagnosed as chronic immune 
thrombocytopenia were enrolled in the study. Helicobacter Pylori infection was documented by Helicobacter pylori stool 
antigen (HpSA) enzyme immunoassay method (EIA). Frequencies were calculated. Chi-square test and independent 
sample t test were used for comparison. P-value of less than 0.05 was considered statistically significant. 
Results: Helicobacter Pylori infection was detected in 25 out of 59 cases of chronic immune thrombocytopenia. No 
statistically significant differences were seen in H-Pylori positive and negative patients with respect to clinical features 
and laboratory findings except mean platelet count, which was lower (57.95±15.1) in Helicobacter Pylori negative as 
compared to positive patients (71.44±18.8). 
Conclusion: We found no significant difference between the clinical and laboratory attributes in H Pylori positive and 
negative cases. Significant finding of high platelet count in Helicobacter Pylori positive patients, may perhaps narrate the 
possible association. 
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I n t r o d u c t i o n  
 
Immune Thrombocytopenic Purpura (ITP) is an acquired 
immune condition defined by a low platelet count 
secondary to rapid platelet destruction by autoantibodies 
against platelet.1, 2 ITP is diagnosed as decreased 
platelets on the blood smear and the exclusion of other 
causes of thrombocytopenia.1, 2 As ITP is caused by anti-
platelet antibodies, the reason of the autoimmune disease 
remains enigmatic. Several immunological studies have 
still not explained why some persons generate anti-
platelet antibodies leading to ITP, while the great majority 
of people do not. The yearly incidence of adult ITP ranges 
1.6-3.9 per 100,000 per year.2 The assessed female-to-
male ratio ranges between 1.2-1.9.2  
ITP is classified based on the presence or absence of 
other underlying diseases (primary or secondary), patient 
age (adult or childhood ITP) and duration of 
thrombocytopenia (acute, persistent or chronic).2  ITP in 
adults commonly is chronic in nature and progresses 
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insidiously, seen mostly in females and less likely 
resolves spontaneously.2 Conversely adult ITP commonly 
occurs without a clear provoking event and mostly leads 
to chronic disease and patient may present with moderate 
to severe bleeding 1. Chronic ITP is more commonly seen 
in older people being twofold greater in people older than 
60 years, and rises with time.3 Gender variance 
disappears with progression of age.3 
Immune thrombocytopenia may follow secondarily in 
certain infectious diseases, lymphoproliferative diseases, 
autoimmune disorders and drugs.4 Among the infections, 
Helicobactor Pylori is an important etiological factor as its 
existence can cause the persistence of disease.5 
The aim of this study was to determine the frequency of 
Helicobacter pylori infection in adult ITP patients and 
secondly to compare the clinical and laboratory aspects 
between positive and negative patients with ITP. As local 
published data is limited on this disease and it may be 
anticipated that frequency might be different in our 
population as compared to international studies. Study will 
be beneficial as patients could be offered eradication 
therapy if deemed appropriate. 
P a t i e n t s  a n d  M e t h o d s  
This cross sectional study was conducted in Hematology 
Unit, Liaquat National Hospital, Karachi. Calculated 
sample size was 55 by using confidence interval 95%, 
precision 10% and prevalence 83%.7 To overcome the 
possibility of dropouts we enrolled 59 adult patients 
suffering from ITP by non-probability consecutive 
technique. Study duration was 19 months from May 2013 
to Nov 2014. Patients with more than six months history 
of bleeding with thrombocytopenia or asymptomatic 
thrombocytopenia with platelet count below 150x109/L 
were enrolled. Patients recently treated for H-pylori 
eradication therapy, history of malignancy or chronic liver 
disease and those who were on medication known to 
cause thrombocytopenia were excluded. Bone marrow 
failure, disseminated intravascular coagulation and 
patients with hypersplenism were also excluded. An 
informed consent was taken from each enrolled patient. 
Patient’s history and physical examination was 
conducted. After thorough clinical evaluation, stool 
samples were collected in a plain container. Antigen of H-
pylori was detected from stool sample by immunoassay 
methodology. Results were reported as positive or 
negative. The specificity and sensitivity of the test were 
96% and 83% respectively. Confounding variables and 
bias were controlled by following the strict exclusion 
criteria. Data was compiled and analyzed through 
Statistical Package of Social Sciences (SPSS) version 13. 
Mean±SD was calculated for the quantitative variables 
i.e. age, platelet count, hemoglobin, hematocrit, MCV, 
MPV and WBC count. Frequency and percentages were 
calculated for qualitative variables i.e. gender and 
outcome (H-pylori antigen). Chi-square test was used to 
analyze association between qualitative variables. 
Independent t-test was used to determine significant 
difference in quantitative variables.  P-value < 0.05 was 
considered as statistically significant.  
R e s u l t s  
Out of 59 patients, 36 were females (61.0%) and 23 were 
males (39.0%), with mean age of 40.95±14.82 years. 
Mean age of the H-Pylori positive and negative patients 
was 42.83±14.5 years and 39.9±15.9 years respectively 
(p=0.4). Total 25(42.3%) patients out of 59 were positive 
for H-Pylori antigen. Among the total patients, 28 (47.4%) 
cases were symptomatic and 31 (52.6%) were 
asymptomatic at the time of presentation. Symptomatic 
patients had mild mucosal bleeds and none had visceral, 
intracranial or life threatening bleeds.  
Table 1: Comparison of  clinical features between 
Helicobacter pylori positive and negative patients with 
ITP (n=59) 
Parameters H pylori 
positive 
(n= 25) 
 
H pylori 
negative 
(n= 34) 
 
p- 
value 
 
 
Age (years) 
Mean±SD 
42.83 ± 14.5 39.9 ± 15.9 0.44 
Male; n (%) 9(36) 14(41) 0.25 
Female; n (%)  16(64) 20(59) 0.25 
Asymptomatic; n 
(%) 
11 (44) 17 (50) 0.38 
Symptomatic; n 
(%) 
14 (56) 17 (50) 0.38 
Dry purpura;  
n (%) 
8 (32) 9 (26.5) 0.31 
Wet purpura; 
 n (%) 
6 (24) 8 (23.5) 0.21 
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The difference between the age, gender and clinical 
symptoms of H-Pylori positive and negative group was 
statistically insignificant (Table 1). 
Regarding laboratory results, comparison of platelet count 
was statistically significant between positive and negative 
groups (Table-2).  
 
D i s c u s s i o n  
Helicobactor Pylori association with immune 
thrombocytopenia was first time reported by Gasbirrini et 
al from Italy in 1998, in which significant increment in 
platelet count was observed, after bacterium eradication.6 
Afterwards many studies from Italy and Japan reported 
the causative role of H-Pylori in ITP and platelet 
augmentations were seen after eradication therapy.7-10 
Helicobacter pylorus is a gram-negative microaerophilic 
bacterium that inhabits the human stomach of more than 
50% of the world population. H-pylori have evidently been 
occupied in the pathogenesis of gastric and duodenal 
ulcers, gastritis and gastric malignancy.11 Numerous 
studies have proposed that H. pylori infection may be 
linked with various disorders, comprising pernicious 
anemia, autoimmune neutropenia, Henoch-Schoenlein 
purpura, membranous nephropathy, autoimmune thyroid 
disease and immune thrombocytopenic purpura (ITP).12   
Various studies have shown the link among H-Pylori and 
ITP. With respect to ITP, role of H-pylori as a causative 
agent has provided conflicting results. Many reports 
mainly from Japan show a strong association between the 
two. Ando K et al reported 83% (50/61) of patients with H-
pylori infection in ITP patients.7 Some Pakistani studies 
on ITP have also found a strong association with H-pylori. 
Shaikh et al reported 63% of H-Pylori infection in chronic 
ITP patients.13 However in American and French 
population the frequency seems to be low. Michel et al 
reported 29% (15/51) positivity of H-Pylori in chronic ITP 
patients.14 H-pylori bacterium is easily eradicated and 
patients with positive H-pylori, ITP may have recovery 
from thrombocytopenia by the short term eradication 
therapy.  
A local study from Pakistan shows the association, where 
H-Pylori infection was found high when compared with 
controls.13 This study reported 43.3% prevalence in 
general control population compared with 63.3% in 
diseased patients.13 Some studies from Turkey, Iran and 
Korea also favor this association.14-18 We could not 
establish a correlation of H-Pylori infection in our ITP 
patients, as the difference between H Pylori positive and 
H Pylori negative in chronic ITP patients was statistically 
insignificant. The association between the two is also not 
seen in studies from France, Spain and Northern 
America, where the prevalence in general population is 
same as in chronic ITP patients 14, 19, 20 
The mechanism by which H-Pylori can cause 
thrombocytopenia is unclear but the pathogenetic 
virulence factors of H pylori such as CagA and VacA are 
known to play the main role.21-23 Several hypotheses have 
been advanced regarding the mechanisms by which H-
pylori may cause ITP. One of the mechanism is the 
molecular mimicry, according to this, H pylori could initiate 
antibody formation secondary to antigens that cross-react 
against various antigens of platelet glycoprotein.5 The 
important role of CagA-positive H-Pylori strains as a 
pathogenic bacterium for ITP was recognized in molecular  
Table 2:  Comparison of laboratory results between Helicobacter pylori positive and negative patients with 
ITP (n=59) 
Parameters H. Pylori positive patients 
(n= 25) 
mean±SD 
H. Pylori negative patients 
(n= 34) 
mean±SD 
p- value 
Hemoglobin (gm/dl) 12.21± 1.47  gm/dl 11.98 ±1.82 >0.05 
Hematocrit (%) 38.23±1.78 37.53±2.37 >0.05 
TLC (109 /L) 8.39 ± 2.86 7.63± 2.84 >0.05 
MPV(fL) 10.80±1.42fl 9.63±0.95 >0.05 
MCV (fL) 83.13± 8.74  fl 86.67 ±8.98 >0.05 
Platelets (µL) 71.44±18.8 57.95±15.1 0.03 
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Table 3: Brief overview of previous studies showing H-Pylori positive ITP patients 
Authors Total 
Particip
ants (n) 
Male/ 
Femal
eRatio 
Infected 
persons 
n(%) 
Age (years) of 
Infected 
persons 
(mean±SD) or 
median(range) 
Age (Years) of 
Non infected 
persons 
(mean±SD) or 
median(range) 
Plate 
Count(µL) of 
Infected 
persons 
Plate Count 
(µL) of Non-
infected 
persons 
(mean±SD) 
Gasbarrini et al. 
(1998)6 
18 5/13 11 (61) 43±14 49±12 95±39 103±24 
Jarque et al. 
(2001)19 
56 18/38 40 (71) 54(17-80) NA 57±22a 58±23 
Kohda et al. 
(2002)27 
40 12/28 25 (62) 54±14 48±13 67±54 NA 
Hino et al. (2003)8 30 8/22 21 (70) 55±15 51±17 38±20 22±12 
Hashino et al. 
(2003)30 
22 9/13 14 (64) 53.2±12.9 41.8±18.6 61±26 63±20 
Ando et al. (2003)7 61 12/49 50 (82) 58±11 40±16 56±24 42±24 
Michel et al. 
(2004)20 
74 21/53 16 (22) 52.5± 15.9 38.5±18.3 34 (Mean) 43 (Mean) 
Takahashi et al. 
(2004)22 
20 5/15 15(75) 54±13 46±18 40±27 39±22 
Sato et al. (2004)32 53 16/37 39 (74) 62 (37-87) 52 (39-77) 55 (19-99) 56 (20-97) 
Ando et al. (2004)31 20 5/15 17 (85) 62 (38-83) NA 48 (4–86) 41 (12–82) 
Nomura et al. 
(2004)10 
42 15/27 28 (66) NA NA 29±6 31±5 
Veneri et al. (2005)9 43 18/25 43 (100) 52 (28-78) NA 54±29 NA 
Inaba et al. (2005)33 35 11/24 25 (71) 57 (25-82) 52±26f 40 NA 
Stasi et al. (2005)36 137 57/80 64 (47) 58±13 42±16 42±25 46±23 
Fujimura et al. 
(2005)38 
435 120/31
5 
300 (69) 59±14 47±16 NA NA 
Suzuki et al. 
(2005)34 
36 NA 25 (69) NA NA NA NA 
Suvajdzic et al. 
(2006)35 
54 12/42 39 (72) 54±13 42±16 68±32 78±32 
Kodama et al. 
(2007)37 
116 32/74 67 (58) 57.9±14.3 47.8±17.2 39±29 30±24 
Tag HS, et al 
(2010) 39 
25 18/7 23(92) 55(35-76) NA 78 (6-96) NA 
Gan GG,et al 
(2013) 40 
50 12/38 11 (22) 50(19-71) 49(18-79) 58 (24-100) 52(8-97) 
Hwang JJ et al 
(2016)41 
102 42/62 42(41)  52.9±19.3 53.0±11.1 43.2±29.1 43.1±28.9 
Sheema et al, 
(2017)42 
85 37/62 34 (40) 43.89 ± 7.06 44.75 ± 7.91 12.3 ± 3.7 13.5 ± 4.1 
Present study 59 23/36 25 (42.3) 42.8(14.5) 39.9(15.9) 71.4 57.9 
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studies.5 They first reported a decrease in platelet-
associated  immunoglobulin-G in ITP patients after H 
pylori eradication as well as the existence of a molecular 
mimicry between the platelet-associated antibodies and 
the Cag-A protein.8 The second study stated that 
antibodies against Cag-A cross-react with a peptide 
expressing on platelets of patients with ITP.23 Although 
the prevalence of H-Pylori is much higher in developing 
countries including India, Bangladesh and Pakistan but 
we are not aware of the strain of bacterium in our 
population.24, 25 
In our patients, no difference in maternal characteristics 
was seen in H-Pylori positive and negative groups. 
Findings of many related studies are similar to us but 
increased prevalence of H-Pylori with increasing age is 
seen in some of the studies mainly from Japan.7, 11, 26, 27 In 
Japanese population, the H pylori was seen significantly 
in older patients and had more cases of hyperplastic 
megakaryocytes in the bone marrow compared to those 
patients without H pylori infection.28 An analysis of 20 
reported series world-wide showed that 873 ITP patients 
were H-Pylori positive out of 1367 (64%) (Table-3).The 
suspicions concerning the definite role of ordinary 
eradication treatment warranted a study in which 37 
known ITP patients of both H-Pylori positive and negative 
were treated with triple regime therapy, 16 of 26 (62%)  
patients were responders who were H pylori positive, 
while in  the H pylori negative patients none was 
responder.29 The improved platelet count in patients who 
took PPI single therapy could have been facilitated by a 
decrease in the amount of H pylori and a bacteriostatic 
influence of the treatment.  
Limitations of the study: These include, small sample 
size and lack of a control group for comparison. Another 
limitation of our study was inaccessibility of data 
concerning the bacterium strain identification and 
eradication therapy. A large sample size would be better 
indicator of comparison between H pylori positive and 
negative patients with ITP. 
C o n c l u s i o n  
The frequency of H pylori infection in our ITP patients was 
42%. The comparative analysis of immune 
thrombocytopenic patients with H pylori positivity and 
negativity based on clinico-hematological features 
revealed no significant difference in the present study. 
Future studies with larger sample size and association 
with eradication therapy will be required to confirm this 
finding. 
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